Introduction to the Basic IP Valuation Issues
Topics

- What is IP Valuation?
- Intangibles – Subject Matter of TT Agreements
- Qualitative and Quantitative Valuation
- Basic IP Valuation Methods and Approaches
- Practices of European R&D Institutions
- Conclusions
What is IP Valuation?

- Valuation: The process of identifying and measuring benefit and risk from an intangible asset.
  - Benefit
  - Risk
Intangibles – Subject Matter of TT Agreements

- **Intangible assets** – non-monetary assets.

- “**Legal Intangibles**” – Intellectual property (IP) refers to creations of the mind: inventions, literary and artistic works, symbols, names, images and designs used in commerce. Once protected under the relevant IP laws – IP becomes legally enforceable right.
  - Patents
  - Trademarks
  - Brands
  - Industrial Design
  - Copyright
  - Trade Secrets / Know-How etc.

- IP is not an asset by itself – only when strategically managed by skilled professionals.

- Number of patents or other protected IP is not an indicator of innovative effectiveness of the organization, the most important is IPR management and results achieved – added value.

- “**Competitive Intangibles**” – impact competitiveness, efficiency, reduce costs, increase revenues, etc
  - Human capital – primary source of competitive intangibles
  - Collaboration activities
  - Organizational processes
  - Know-How
  - Business Plan
  - List of partner institutions
  - Reputation.
When is IP Valuation Used?

- Litigation
- IP audit (management tool)
- Licensing
- Joint ventures (collaborations)
- Merger and acquisition
- Financial reporting
- Financing
- Investment transactions
IP Valuation in R&D Environment

- Tool in a decision making process – provides management with useful information as a base for decisions in pre commercial and commercialization phase;
- Important part of the technology transfer processes – collaborations, sponsorships, licensing, establishing of the start-ups, etc;
- Enables fund raising;
- Communication tool – about the value of technologies developed by R&D, and products based on them;
- Supports learning process – how to add value to the organizational processes, human capital, research results, IP etc;
- Monitoring on return on investment;
- Litigation – rare situation for publically funded research institutions.
Intangibles – Subject Matter of TT Agreements

- Technology transfer agreements have as a subject matter Intangible Assets – in particular intellectual property;
- Licensing Agreement – IP is an exclusive subject matter;
- Collaboration Agreement;
- Sponsored Research Agreement;
- Material Transfer Agreement;
- Consultancy Agreement;
- Confidentiality Agreement;
- Research Service Agreement, etc.
Public policies supporting commercialization of publicly funded research

World PRO and university PCT applications, absolute numbers (left) and as a percentage of total PCT applications (right), 1980-2010
Rise of Tradability of IP

International royalty and licensing fee (RLF) receipts increased from USD 2.8 billion in 1970 to USD 27 billion in 1990, and to approximately USD 180 billion in 2009 – outpacing growth in global GDP.

RLF payments and receipts, in USD millions (left) and as a percentage share of GDP (right), 1960-2009
Intangible Assets Valuation – What is so Different than Valuating Tangibles?

- Valuation – The process of identifying and measuring financial benefit of an asset.
- Valuation of Intangibles – The process of identifying and measuring financial benefit and risk of an asset, in a particular context.
- Risk
  - Time – What is the time needed to bring technology on the market? Sometimes even breakthrough technology can be « too early » for the market.
  - Money – How much more do we need to invest?

Risk is a particularly important element in the valuation of early stage technologies – more time and money needed to bring technology on the market – less value.
Risk and Money?

Closer to the market, with and without financial partner – the value of IP will be different for the same asset.
Intangible Assets Valuation – What is so Different than Valuating Tangibles?

- The price is not the value of an intangible asset, while the price of a tangible asset is usually the expression of the real value.
- The price is what is proposed to the other side of the deal and it depends on how « thirsty » is the other side for that particular technology.
- The value of an intangible is the financial benefit that an asset can generate in a particular context, taking fully into account the risk that the investment in the development of the asset may be higher than realized value.
- The potential value of intangibles depends on the context in which that value will be realized.
Intangible Assets Valuation – What is so Different than Valuating Tangibles?

- Most intangibles are capable to generate more than one value stream simultaneously.
- In certain contexts the value is determinate by the authority, relevant laws (tax laws) or empirical experiences.
- It is important to define approach to value:
  - Understand actual value of an asset in use for actor,
  - Potential value in use,
  - Value construction – for negotiation purposes.
Qualitative and Quantitative Valuation

- IP valuation is both qualitative and quantitative in nature, as calculations are always based on qualitative analysis.
- **Qualitative methods** provide a value guide through the rating and scoring of IP based on factors which can influence its value.
- It examines, at a **micro level**:
  - the quality of intangible assets themselves;
  - their position and importance, relative to other business drivers;
  - the broader industry within which the business operates;
  - the potential value for business’s competitors and potential competitors.
- The **macro-economic outlook**, over the useful life of the intangibles, for the economy in which the business operates.
Qualitative Valuation

The qualitative study is used to formulate (and justify) assumptions on which the financial models, used to determine a numerical value to the IP under consideration, will be based.

Rating & Scoring

Components

(1) Scoring criteria
(2) Scoring system
(3) Scoring scale
(4) Valuing factors, and
(5) Decision rules.
Qualitative and Quantitative Valuation

Quantitative methods attempt to calculate the monetary value of the IP and include:
- Cost
- Market
- Income
- “Rule of Thumb”
- Monte Carlo
- Industrial Standard
- Real Option
- Other Methods.
IP Valuation Methods and Approaches

**Cost Method**

- Cost-based models approximate IP value by determining the replacement/creation around cost of equivalent IP.
- The approach, while useful in the situation where there is no other available data – wholly disregards the innovation and uniqueness of the IP.
- There is no “equivalent” or “identical” IP – that negates the novelty and inventiveness – that define intangible assets.
- Intangible assets tend to grow over time, use and investment so their full value is not apparent at inception – that is why it is so difficult to project a real commercial value of early stage technology.
IP Valuation Methods and Approaches

- **Cost Method**

- Correlation between the cost and value may arguably be used:
  - at the pre-commercialization outset of the IP;
  - as a starting point for licensor (R&D institution) in constructing a negotiation value of the IP – licensor would like to cover the costs of development of technology and protection of the IP;
  - helps to understand the position of the other negotiation party.
IP Valuation Methods and Approaches

- This method is more appropriate for tangible assets – where cost reflects the value of the asset.

- **Disadvantages of the Cost Method:**
  - Limited effect;
  - Does not show earning power of the technology and ultimate market share;
  - Cost to “create around” – not an indicator of the value of an asset as with the time needed the technology may become obsolete;
  - “Creating around” – there is a potential danger of an infringement of the model technology;
  - Cost of development – totally wasted or dramatically understated value of the product or service.

- In TT negotiation “cost of the development” of technology is rarely accepted as an argument – “I do not want to pay for an inefficient licensor!”
IP Valuation Methods and Approaches

Market Approach

- Postulates intellectual property value as the amount for which equivalent IP was either sold or offered for sale on the open market.
- As the cost approach, there is an assumption of the existence of intangible assets that are sufficiently equivalent to those being valued.
- Does not take into account that in the contractual context the IP is valued in correlation with other key terms of the agreement – exclusivity, territorial aspects, duration, available know-how, post contractual services, etc.
- The approach also suffers from the scarcity of available information – IP market is still not sufficiently developed.
- If a sale price / royalty rate is made public, the amount allocated to IP from the total purchase price is not reported or other terms of contract are unknown.

Useful:
- For tempering future-income-based forecasts;
- For valuation of early stage technology – as a starting point in income based valuation, if there is no other indicators for determining the price of the future product containing new technology.
IP Valuation Methods and Approaches

Disadvantages of the Market Approach:

- Difficult to find similar transactions;
- If used following comparability factors should be identified:
  - Relevant time period – the future is a focal point! Expected cash flow – not price paid!
  - Financial situation of the parties – are both parties on equal footing?
  - Relevant industry transactions – similar technology in a similar industry sector – each industry has a set of unique economic forces:
    - Consumer electronics – highly competitive;
    - Airlines – oligopolies;
  - Foreign transactions – relevant only in the countries with similar economic development and legal framework;
  - What are complementary asset investment requirements – high infrastructure pre investment will diminish the value of IP;
  - Non-monetary compensation – “grant backs”, “technology share”;
  - Independent status of the parties – negotiations are different if parties are in alliances and joint ventures (Merck & Co – Johnson & Johnson).
IP Valuation Methods and Approaches

**Income Method:** Projection of the future revenues that the IP asset can be expected to generate on the market over a certain period of time taking into account the time, value of the money and the risk that the income will not be realized.

**Essential Elements of the Projection**
- **Market Penetration**
- **Sales Forecast (sales growth)**
  - Conditions of the general economy;
  - Developments in the industry in which product will be produced;
  - Conditions that will influence customers;
  - Competitors reaction.
- **Time**
- **Changing Value of Money (over the time)**
- **Risk**

**Pre-commercialization costs** – should be also taken into consideration.

**Production Costs** – difficult to predict for an early stage technology, previous experience with similar technology can be an useful foundation.

**Overhead costs** – historical experiences
- Advertising;
- Education about the new product;
- Promotion of product on fairs;
- Discount promotional fees;
- Development of related intangible assets (know-how, services, training etc.).
IP Valuation Methods and Approaches

Different Approaches of Income Method
- Discounted Cash Flow
- Monte Carlo
- Real Option
- Royalty Revenues
- “Rule of Thumb” – 25% Rule
Income Method – Discounted Cash Flow Approach (DCF)

- DCF is the most frequently used approach of the Income Method;
- A projection of a future net cash flow expected from the commercial use of an intangible asset under review;
- Over a period of the economic life of the IP;
- “Discounted” by the time value of the money and risk (“discounted rate”);
- Objective: determination of the Net Present Value of the IP asset.
How DCF Calculation Works (continued)

\[ PV = \sum_{t=1}^{n} \frac{CF(t)}{(1+r)^t} \]
Example – “Smart Turbine”

- Combination of “wind-solar” turbine technology was developed by the university and licensed to a big, well known multinational company;
- It was envisaged that the product will be ready for selling in 2013;
- Potential cash flow on 10 top markets for renewable energy was estimated on about 10,5 billion Euros in 2013, with the forecasted growth of 16% per year;
- Period under review – 6 years;
- Penetration rate – 10% of the potential market cash flow in the first year, 30% in the second, 60% in the two following years. Valuator estimated that the sales of the technology will decline in the last years under the review and that the “curve” of penetration will move towards 50% and than 40% of the market share;
- Discount (risk) rate was determinate to be 8%.
<table>
<thead>
<tr>
<th>Period of the review (year)</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Expected economic growth of total new turbine market (16%)</strong></td>
<td>10.5 BE</td>
<td>12.18 BE</td>
<td>14.12 BE</td>
<td>16.38 BE</td>
<td>19.02 BE</td>
<td>22.04 BE</td>
</tr>
<tr>
<td><strong>Market penetration rate for Smart Turbine tech.</strong></td>
<td>10%</td>
<td>30%</td>
<td>60%</td>
<td>60%</td>
<td>50%</td>
<td>40%</td>
</tr>
<tr>
<td><strong>Projected cash flow for Smart Turbine tech</strong></td>
<td>1.05 BE</td>
<td>3.65 BE</td>
<td>8.47 BE</td>
<td>9.83 BE</td>
<td>9.6 BE</td>
<td>8.96 BE</td>
</tr>
<tr>
<td><strong>Net Cash Flow (10%)</strong></td>
<td>0.105 BE</td>
<td>0.365 BE</td>
<td>0.847 BE</td>
<td>0.983 BE</td>
<td>0.96 BE</td>
<td>0.896 BE</td>
</tr>
<tr>
<td>Discount factor</td>
<td>$\frac{1}{(1.08)}$</td>
<td>$\frac{1}{(1.08)^2}$</td>
<td>$\frac{1}{(1.08)^3}$</td>
<td>$\frac{1}{(1.08)^4}$</td>
<td>$\frac{1}{(1.08)^5}$</td>
<td>$\frac{1}{(1.08)^6}$</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Discounted value of 1 Euro</td>
<td>.926</td>
<td>.857</td>
<td>.794</td>
<td>.735</td>
<td>.681</td>
<td>.630</td>
</tr>
<tr>
<td>Discounted Cash Flow</td>
<td>0.097 BE</td>
<td>0.313 BE</td>
<td>0.673 BE</td>
<td>0.723 BE</td>
<td>0.654 BE</td>
<td>0.564 BE</td>
</tr>
<tr>
<td>Net Present Value</td>
<td>3,024 BE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DCF – Early Stage Technologies

Early Stage Technology – high risk – as there is a delayed time to income and additional investment needed.

- High discount rate counterbalances high risk;
- Delayed income and high discount rate – lower the value of technology;
- Technology risk very high;
- Commercial risk very high:
  - Inflation
  - Competition
  - Changing economic climate.

Expected returns and “paydays” should be proportional to the risk and stage of technology development:
- Start up (protected idea) – 50%
- First stage (prototype) – 40%
- Second stage – 30%
- First stage – 25%
DCF – Early Stage Technology

- Discount rate reflects risk, usually similar in the same industry sector.
- Biotechnology and pharmaceutical industry – early stage technology particularly risky.

- Professional estimations:
  - Discovery – 80%
  - Preclinical – 60%
  - Phase I Clinical trials – 50%
  - Phase II Clinical trials – 40%
  - Phase III Clinical trials – 25%
  - New drug application – 22.5%
  - Product launch – 15%-17.5%

- **Venture capitalists** – short term investors – 5 to 7 years to get out of investment.
- Often VC for an investment in an early stage technology would consider 50% as a reasonable discount rate – and would like to realize proportional return on investment.
DCF Approach in the Context of Licensing

- Value based on a royalty savings hypothesis, essentially asking (and hopefully, answering) the following question: “Over the useful life of the intellectual property, what would I save by owning, rather than licensing, the intellectual property under consideration?”

- Projection of the future royalty stream (instead of “net cash flow”), discounted for the risk and money value over the time.
Monte Carlo

- Monte Carlo Simulation – computer based sophisticated version of the multiple scenario DCF.
- For each DCF element it provides a range of possible values and different options for the distribution of these values.
- It provides projection of thousands scenarios and net present values, in a form of a frequency chart – easy to visualize the probabilities of net present outcomes.
Real Option – 1972 Black and Scholes article – model for valuing financial options (the right to buy or sell a specific asset at the fix price prior to some expiration date) can be used for IP valuation

- Analogies made on the similar volatility of the context between financial options and IP;
- Based on income approach and DCF principles;
- Mathematically very complex;
- Required inputs difficult to determine:
  - Current value of the asset – NPV – as a starting point;
  - The variance of the value of the asset in the future (similar as volatility of the stock);
  - Expected income generated by the asset ("dividend – paid" for option – "net cash flow");
  - "Strike price" of the option – investment needed to launch the product;
  - "Economic life" of an asset – the time before expiration of the option;
  - Riskless interest rate – during the economic life of the option – long time government bond.

- Real option method is considered by some expert as particularly applicable for valuation of an early stage technology.
Industrial Standard

- **Standard Industrial Royalties**
- Some industries have developed standard royalty rates over the years based on what could be considered “rules of thumb”.
- Inconvenient for IP – patents and other IP aren’t commodities and thus can not be accurately valued at a set rate.
- However, if a patent is being valued for an **external transaction** within an industry that traditionally applies standard royalty rates, then the use of this standard rate in the valuation can not be totally dismissed.
- For an internal valuation, the use of standard royalty rates is not recommended.
### Table 1. Running Rates by Agreement Type and Industry

<table>
<thead>
<tr>
<th>Agreement Type</th>
<th>Industry</th>
<th>All (Median)</th>
<th>Software (Median)</th>
<th>Hardware (Median)</th>
<th>Medical (Median)</th>
<th>Pharma (Median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Types</td>
<td></td>
<td>5.0% (8.2%)</td>
<td>10.0% (17.3%)</td>
<td>5.0% (7.0%)</td>
<td>5.0% (5.6%)</td>
<td>5.0% (6.2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 2,963</td>
<td>n = 515</td>
<td>n = 489</td>
<td>n = 520</td>
<td>n = 1,439</td>
</tr>
<tr>
<td>Product/</td>
<td></td>
<td>10.0% (15.4%)</td>
<td>14.4% (18.9%)</td>
<td>6.0% (12.8%)</td>
<td>5.0% (7.9%)</td>
<td>8.0% (12.6%)</td>
</tr>
<tr>
<td>Distribution²</td>
<td></td>
<td>n = 339</td>
<td>n = 180</td>
<td>n = 58</td>
<td>n = 44</td>
<td>n = 57</td>
</tr>
<tr>
<td>Development/JV³</td>
<td></td>
<td>6.5% (9.5%)</td>
<td>17.0% (21.2%)</td>
<td>4.0% (8.1%)</td>
<td>6.0% (6.7%)</td>
<td>6.0% (7.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 482</td>
<td>n = 65</td>
<td>n = 71</td>
<td>n = 53</td>
<td>n = 293</td>
</tr>
<tr>
<td>Acquisition⁴</td>
<td></td>
<td>5.7% (9.1%)</td>
<td>10.0% (16.4%)</td>
<td>5.0% (6.4%)</td>
<td>5.0% (6.1%)</td>
<td>5.0% (6.8%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 350</td>
<td>n = 90</td>
<td>n = 78</td>
<td>n = 56</td>
<td>n = 126</td>
</tr>
<tr>
<td>Settlement⁵</td>
<td></td>
<td>5.0% (6.1%)</td>
<td>4.6% (7.6%)</td>
<td>6.0% (7.1%)</td>
<td>5.0% (5.5%)</td>
<td>4.6% (5.9%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 87</td>
<td>n = 10</td>
<td>n = 12</td>
<td>n = 33</td>
<td>n = 32</td>
</tr>
<tr>
<td>Patent (+)⁶</td>
<td></td>
<td>4.5% (5.1%)</td>
<td>4.0% (4.4%)</td>
<td>4.4% (4.9%)</td>
<td>5.0% (5.4%)</td>
<td>4.5% (5.1%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 570</td>
<td>n = 17</td>
<td>n = 95</td>
<td>n = 109</td>
<td>n = 349</td>
</tr>
<tr>
<td>Research⁷</td>
<td></td>
<td>4.0% (4.4%)</td>
<td>5.5% (5.5%)</td>
<td>3.0% (5.3%)</td>
<td>3.6% (4.0%)</td>
<td>4.0% (4.4%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 118</td>
<td>n = 2</td>
<td>n = 5</td>
<td>n = 18</td>
<td>n = 93</td>
</tr>
<tr>
<td>Bare Patent⁸</td>
<td></td>
<td>3.0% (3.7%)</td>
<td>3.0% (3.3%)</td>
<td>3.5% (3.9%)</td>
<td>3.5% (3.9%)</td>
<td>3.0% (3.6%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 343</td>
<td>n = 17</td>
<td>n = 56</td>
<td>n = 73</td>
<td>n = 197</td>
</tr>
<tr>
<td>Other⁹</td>
<td></td>
<td>5.0% (8.9%)</td>
<td>11.6% (18.1%)</td>
<td>5.0% (6.9%)</td>
<td>4.0% (5.6%)</td>
<td>5.0% (6.9%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 674</td>
<td>n = 134</td>
<td>n = 114</td>
<td>n = 134</td>
<td>n = 292</td>
</tr>
</tbody>
</table>
“Rule of Thumb”

- Licensor, as developer of the technology, considers as a fair deal to get 25% - 33% of the licensee’s profit (not income).
- Different opinions about the value of the method.
- In practice often used as an indicator.
- Recently formally forbidden in US litigation.
Practices of European R&D Institutions

Survey of European “TTO Circle”
October 2011
In a given year, how often on average do you perform valuation of early stage technologies?

Group I – Performing Valuation 1 – 20 times per year
Group II - Performing Valuation 40 – 50 times per year
Group III – Performing Valuation more than 100 times per year
Do you perform valuation of early stage technology internally or do you use external consultants?

Group I – Only Internal Resources
Group II – Combination of Internal Resources and Consultancy
Group III – Only Consultancy
Can you please give an estimate of the internal human resources used for performing valuation of early technologies on average on a yearly basis?

Group I - 0.25 to 1 man/month/year
Group II - 1 – 25 man/month/year
Group III - 30 to 100 man/month/year
Can you please give an estimate of the budget dedicated to the use of external consultants for the valuation of early stage technologies?

Group I – 500 – 20 000 Euros
Group II – 50 000 – 200 000 Euros
Group III – 800 000 – 1 000 000 Euros
Group I – Using “combination” of the methods for valuation of the early stage technology
Group II – Using only Qualitative method
Can you please indicate which qualitative method(s) you use to valuate technologies (e.g. rating, ranking, scoring methods)?

- Focus of the **qualitative** approach is the analyze of the **quality of the technology** from different standpoints:
  - Technical – development status (early stage, proof of concept, pilot..);
  - IP point of view (solidity of the patent, degree of novelty, freedom of operation);
  - Market point of view – existence of similar technologies and their geographical distribution, potential partners;
  - Financial.

- **Internally developed ranking criteria, such as “8 leading factors”:**
  - Suitability for Suggested Application
  - Cost
  - Development Status
  - Exploitation Rights
  - Degree of Novelty
  - Marketing Interest of Partner
  - Quality of Technology Information
  - Sociability of Technology Provider

- **Or**
  - Patentability
  - Patent Strength
  - Status of Invention
  - Market Situation
  - Inventor’s History – Supportive or not in the process of transfer?
  - Additional Services for the Partner (potential for continuation of collaboration)
  - To whom shall invention be licensed

- In addition some institutions are using **“competence “ criteria – scientific and management skills of the team.**
Can you please indicate which quantitative method(s) you use to valuate technologies (e.g. market approach, income based)?

- One third of the participating institutions did not give concrete response.
- “Finger in the air” - we still do not use quantitative valuation methods!”
- “Informal one, without rigorous framework” – or
- Defined “pricing policy” for services, trainings etc.
- Majority of the respondents are using a combination of few different tools.
- The most frequently used method is Income Method – 77% of the responses indicated IM.
- Income method is used in a variety of its approaches – mostly Discounted Cash Flow (NPV), 25 % (one organization) and Monte Carlo approach in combination with other methods (one organization).
- Market / Comparable Method – 44,5 %.
- Cost Method – in combination with other data – patent based and know how based – two organizations.
- Industry standards – one organization.
- Scoring based on quantitative information – one organization.
In the case of licensing, how do you transform the value of a particular technology to obtain its "price" to be paid by the licensee?

- Pragmatic approach and bottom line – “price” has to cover cost of:
  - Development of the technology;
  - IP protection;
  - Incentives for the researchers.

- Negotiation approach – valuation supports negotiation strategy, but the real “price” depends on what the partner is ready to pay – how “hungry” for technology he is!!

- Price is in some institutions always determined by the experienced staff of the institution.

- Some institutions have particular rules:
  - Royalty rate is always 10% of the net sales price.
  - The total income should be 25% of the NPV.
  - Market comparisation of the royalty rates of the product.
Can you please give the reason(s) for choosing a different approach in the case of early stage technologies valuation related to the creation of spin-off companies:

- Creation of the spin-off involves two aspects:
  - Valuation of the technology
    - Mixed methods;
    - Higher risk rate;
    - Shorter period of projection – up to 5 years;
    - Equities;
    - Evaluation of the additional elements such as competence of the team.
  - “Stronger” file to be defended in relation with potential investors and VC.
- Licensing Conditions and Pricing
  - “Make the start up fly!!!”
  - Lower upfront payments;
  - Running Royalty Rates instead lump sum or upfront payments;
  - Delayed starting point of payments.
Conclusions

- IP Valuation is an ESTIMATION of an intangible asset value, thus it is not a precise figure.
- It is always qualitative and quantitative, and potentially subjective (having access to more or less same data, two valuators can always come out with different figures).
- Experience is essential!
- In contractual relations it is important to develop “starting point” for negotiation – even if there is a reasonable difference in the projection of the value, it is an advantage to be able to show reasoning behind the “value structure”.
Thank you!

Olga Spasic
Innovation and Technology Transfer Section
Patents and Innovation Division
olga.spasic@wipo.int